Virginie Buggia-Prevot, PhD

Senior Director, Drug Discovery Valo Health

Dr. Virginie Buggia-Prevot is a neurobiologist/cell biologist with over 15 years of experience in academia and the biotechnology sector. She is currently Senior Director of Drug Discovery at Valo Health, a tech­nol­o­gy com­pa­ny using human-cen­tric data and arti­fi­cial intel­li­gence (AI) pow­ered compu­ta­tion to transform the drug dis­cov­ery and devel­op­ment process, and has been at the company for more than two years. In her role she leads neurology discovery, developing human-centric computational approaches to discover new targets for neurodegenerative diseases. Prior to Valo, Virginie led novel target discovery and validation for Alzheimer’s disease at the Neurodegeneration Consortium, MD Anderson, an academic collaboration of leaders in the field of neurodegeneration from the Baylor College of Medicine, Massachusetts Institute of Technology, Icahn School of Medicine at Mount Sinai, New York University and more. The mission of the Consortium is to better understand the underlying biology of Alzheimer’s disease and translate the knowledge into therapeutic interventions that can effectively alleviate symptoms by delaying, reversing and/or eliminating the pathology of the disease and other neurological diseases. Her work on a neuroprotective small molecule program contributed to the launch of Magnolia Neurosciences, a company focused on the development of a new class of neuroprotective medicines. A new strategic research agreement was formed with Denali Therapeutics from data generated by Virginie and her team.

Dr. Buggia-Prevot received her PhD in cell and molecular biology from the University of Nice Sophia-Antipolis and completed her post-doctoral training at the University of Chicago

Our website uses cookies, including third parties’ profiling cookies, to improve the functionality of the site and your user experience. You can learn more about how we use cookies and how to change your cookies settings in our Privacy Policy. By closing this message, clicking below or continuing to use this site, you consent to our use of cookies.